DA Davidson Maintains Neutral on Medifast, Lowers Price Target to $80
Portfolio Pulse from Benzinga Newsdesk
DA Davidson analyst Linda Bolton Weiser has maintained a Neutral rating on Medifast (NYSE:MED) and lowered the price target from $93 to $80.
August 08, 2023 | 4:24 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Medifast's price target has been lowered from $93 to $80 by DA Davidson, while maintaining a Neutral rating.
The lowering of the price target by DA Davidson could potentially lead to a negative sentiment among investors, which may put downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100